Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Farnesyl transferase (FTase) is an enzyme that catalyzes the posttranslational modification of proteins by attaching a 15-carbon farnesyl isoprenoid group to a cysteine residue near the C-terminus of target proteins. This farnesylation promotes membrane association and proper function of signaling proteins, particularly members of the Ras superfamily. FTase is a heterodimer consisting of alpha and beta subunits, with the active site containing a zinc cation and a hydrophobic pocket for farnesyl diphosphate (FPP) binding. Due to its role in cancer-related Ras protein activation, FTase is an important anti-cancer drug target, with several small-molecule inhibitors developed and tested in clinical trials.
Inhibition of farnesyl transferase prevents Ras protein membrane localization and downstream signaling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Farnesyl Transferase.